Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:60058
Name lymphoma
Definition A hematologic cancer that affects lymphocytes that reside in the lymphatic system and in blood-forming organs.
Source DiseaseOntology.org
Alt Ids DOID:353 DOID:1033
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
NRAS mutant Trametinib lymphoma sensitive detail...
TP53 wild-type ALRN-6924 lymphoma predicted - sensitive detail...
ALK negative CEP-28122 lymphoma resistant detail...
BRAF mutant Trametinib lymphoma no benefit detail...
MAP2K1 F53C Vemurafenib lymphoma predicted - resistant detail...
ALK rearrange Crizotinib lymphoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00084695 Phase II Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status USA 0
NCT00368082 Phase I Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) (TGF-beta) Active, not recruiting USA 0
NCT00585195 Phase I Crizotinib + Itraconazole Crizotinib + Rifampin A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001) Completed USA | AUS 2
NCT00608361 Phase I Dasatinib Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery Completed USA 0
NCT00918333 Phase Ib/II Everolimus + Panobinostat Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma Completed USA 0
NCT01237236 Phase I Ribociclib A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma. Completed USA | NLD | FRA 0
NCT01273155 Phase I Belinostat Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction Completed USA 0
NCT01287546 Phase I Emibetuzumab + Erlotinib Emibetuzumab + Trametinib Emibetuzumab A Study of LY2875358 in Participants With Advanced Cancer Completed USA 0
NCT01326702 Phase Ib/II Veliparib Rituximab Bendamustine Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed USA 0
NCT01327612 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ganitumab Bevacizumab Conatumumab Open Label Extension Study of Conatumumab and AMG 479 Completed USA | POL | ESP 0
NCT01363817 Phase I Dexamethasone BMS-906024 Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Completed USA | FRA | DEU 0
NCT01393509 Phase I PU-H71 The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies Completed USA 0
NCT01473095 Phase I Miransertib Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma Completed USA 0
NCT01498484 Phase II EB-VST cells Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies Completed USA 0
NCT01564251 Phase I GDC-0575 + Gemcitabine GDC-0575 A Study of GDC-0575 Alone And in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma Completed USA | FRA 0
NCT01576406 Phase I Crizotinib Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients Completed USA 0
NCT01596270 Phase I Voxtalisib A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma Completed USA 0
NCT01625351 Phase I Fludarabine Melphalan Busulfan Alemtuzumab A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Completed USA 0
NCT01636479 Phase I SAR405838 Phase 1 Safety Testing of SAR405838 Completed USA | NLD | FRA 0
NCT01638533 Phase I Romidepsin Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Active, not recruiting USA | CAN 0
NCT01655225 Phase I LY3023414 + Midazolam Letrozole + LY3023414 LY3023414 A Study of LY3023414 in Participants With Advanced Cancer Completed USA | ITA 1
NCT01665768 Phase II Rituximab Everolimus Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma Completed USA 0
NCT01670175 Phase I Cyclophosphamide + Sirolimus + Topotecan Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors Completed USA 0
NCT01673737 Phase I SAR260301 SAR260301 + Vemurafenib A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer Completed USA | CAN 0
NCT01695005 Phase I LY3039478 A Study of LY3039478 in Participants With Advanced Cancer Completed USA | GBR | FRA | ESP | DNK | DEU 0
NCT01703481 Phase I Erdafitinib A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Patients With Advanced or Refractory Solid Tumors or Lymphoma Completed USA | FRA | ESP 0
NCT01703572 Phase I Brontictuzumab A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies Completed USA 0
NCT01703949 Phase II Brentuximab vedotin Brentuximab vedotin + Nivolumab Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma Recruiting USA 0
NCT01744223 Phase Ib/II Rimiducid Rivogenlecleucel Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant Active, not recruiting USA 0
NCT01744652 Phase I Crizotinib + Dasatinib Dasatinib and Crizotinib in Advanced Cancer Completed USA 0
NCT01829971 Phase I MRX34 A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection Terminated USA 1
NCT01844583 Phase I Alisertib + Esomeprazole Alisertib + Rifampin Alisertib Safety, Tolerability and PK of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib Completed USA 0
NCT01877382 Phase I Milademetan A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas Completed USA 0
NCT01885897 Phase Ib/II Nogapendekin alfa inbakicept IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT Completed USA 0
NCT01897012 Phase I Romidepsin Alisertib Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas Completed USA 0
NCT01898078 Phase I Alisertib Food Effect Study of Alisertib (MLN8237) in Patients With Advanced Solid Tumors or Lymphomas Completed USA 0
NCT01905228 Phase I CBL0137 A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm or Refractory Lymphomas Completed USA 0
NCT01908413 Phase I GDC-0917 Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma Terminated USA 0
NCT01919619 Phase II Ipilimumab + Lenalidomide Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies Completed USA 0
NCT01943682 Phase I CPX-351 Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma Completed USA 0
NCT01947140 Phase Ib/II Pralatrexate + Romidepsin Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies (PDX+Romi) Completed USA 0
NCT01991938 Phase I VS-5584 Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma Terminated USA | GBR 0
NCT01992653 Phase I Cyclophosphamide + Doxorubicin + Prednisone Rituximab Polatuzumab vedotin-piiq Obinutuzumab A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma Completed USA | FRA 0
NCT01998035 Phase Ib/II Azacitidine + Romidepsin Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies Terminated USA 0
NCT02042989 Phase I Ixazomib + Vorinostat MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies Completed USA 0
NCT02203903 Phase I MultiTAA-specific T cells Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE) Recruiting USA 0
NCT02216409 Phase I Hu5F9-G4 Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody Completed USA 0
NCT02249429 Phase Ib/II PQR309 Open-Label, Non Randomized Phase 2 Study With Safety Run-In Completed USA | ISR | GBR | FRA 2
NCT02259010 Phase I Alisertib Itraconazole A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma Completed USA 0
NCT02287311 Phase I LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes Cyclophosphamide + Fludarabine Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) Recruiting USA 0
NCT02309580 Phase I Ibrutinib Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma Completed USA 0
NCT02318329 Phase I Bemarituzumab Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors Completed USA 2
NCT02323880 Phase I Selinexor Study of Selinexor in Pediatric Solid Tumors Active, not recruiting USA 0
NCT02332668 Phase Ib/II Pembrolizumab A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) Recruiting USA | SWE | NLD | ITA | ISR | GBR | FRA | DEU | BRA 1
NCT02337985 Phase I Rituximab Cyclophosphamide + Doxorubicin + Etoposide + Vincristine Sulfate Filgrastim Prednisone Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT02343718 Phase I Temsirolimus + Vinblastine Vinblastine and Temsirolimus in Pediatric Patients With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours Completed CAN 0
NCT02355535 Phase I PAC-1 Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies Completed USA 0
NCT02356159 Phase Ib/II Cytarabine + Fludarabine Palifermin Prednisone Filgrastim Methotrexate + Sirolimus + Tacrolimus Doxorubicin + Etoposide + Fludarabine + Vincristine Sulfate Cyclophosphamide + Fludarabine Rituximab Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Active, not recruiting USA 0
NCT02376699 Phase I Pembrolizumab + SEA-CD40 SEA-CD40 Safety Study of SEA-CD40 in Cancer Patients Terminated USA 0
NCT02392611 Phase I Exemestane + GS-5829 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Adults With Advanced Solid Tumors and Lymphomas Completed USA 0
NCT02414724 Phase I Gemcitabine + Ribociclib Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma Terminated USA 0
NCT02431260 Phase I INCB054329 An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies Terminated USA 0
NCT02432235 Phase I Camidanlumab tesirine Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma Completed USA | GBR 0
NCT02440685 Phase Ib/II ASN002 A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors Terminated USA | ARG 0
NCT02465060 Phase II Nivolumab + Relatlimab Dabrafenib + Trametinib Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Active, not recruiting USA 2
NCT02477878 Phase I BPX-601 Rimiducid Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant Active, not recruiting USA 0
NCT02499861 Phase Ib/II Decitabine + Genistein Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies Completed CAN 0
NCT02503423 Phase Ib/II ASTX-660 Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas Active, not recruiting USA | ITA | HUN | GBR | FRA | ESP | CAN | BEL 0
NCT02516813 Phase I Peposertib Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy Completed USA | SWE | NOR | NLD | DNK | DEU | CHE | BEL 0
NCT02518113 Phase Ib/II Dexamethasone LY3039478 A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL Completed USA | ITA | ISR | FRA | DEU 0
NCT02518750 Phase II Bortezomib + Dexamethasone + Panobinostat Pegaspargase Mercaptopurine Nelarabine Mitoxantrone Vincristine Sulfate Cyclophosphamide + Etoposide Cytarabine + Methotrexate + Prednisone Clofarabine Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma Terminated USA 0
NCT02518958 Phase I Nivolumab A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab Completed USA 0
NCT02538926 Phase II Imatinib Rituximab Cyclophosphamide Prednisone Doxorubicin + Etoposide + Vincristine Sulfate Asparaginase Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Withdrawn USA 0
NCT02552953 Phase I CYC065 A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers Completed USA 0
NCT02575638 Phase I CZ48 Safety Study of Camptothecin-20-O-Propionate Hydrate (CZ48) Unknown status USA 0
NCT02582827 Phase I ABI-011 QUILT-3.014: A Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas Withdrawn USA 0
NCT02624388 Phase II Genistein Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) Terminated USA 0
NCT02661542 Phase Ib/II FF-10502 Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas Completed USA 0
NCT02663518 Phase I TTI-621 A Trial of TTI-621 for Patients With Hematologic Malignancies Terminated USA | CAN 0
NCT02675439 Phase I Ipilimumab + MIW815 MIW815 Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas Terminated USA 0
NCT02681302 Phase Ib/II Ipilimumab + Nivolumab Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence (CPIT001) Terminated USA 0
NCT02683395 Phase I PLX51107 A Study of PLX51107 in Advanced Malignancies Terminated USA 0
NCT02694822 Phase I Zalifrelimab AGEN-1884, an Anti-CTLA-4 Antibody, in Advanced Solid Cancers Completed USA 0
NCT02729896 Phase Ib/II Obinutuzumab + Polatuzumab vedotin-piiq + Rituximab Atezolizumab + Obinutuzumab + Polatuzumab vedotin-piiq A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Completed USA | POL | DEU 0
NCT02740270 Phase I GWN 323 + Spartalizumab GWN 323 Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas Completed USA | ISR | ESP | CAN 2
NCT02780011 Phase I Alisertib + Brentuximab vedotin Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies Withdrawn USA 0
NCT02780804 Phase I Entinostat Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Completed USA 0
NCT02783625 Phase I Bortezomib + Duvelisib Duvelisib + Romidepsin Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas Active, not recruiting USA 0
NCT02784795 Phase I Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Completed USA | FRA | ESP | DNK 0
NCT02786485 Phase I Rimiducid Rivogenlecleucel Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT Withdrawn 0
NCT02793466 Phase I Durvalumab Durvalumab in Pediatric and Adolescent Patients Completed USA 0
NCT02793544 Phase II Cyclophosphamide Busulfan Sirolimus Mycophenolate mofetil Mesna Fludarabine HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Completed USA 0
NCT02812875 Phase I CA-170 A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas Completed USA | GBR | ESP 1
NCT02846935 Phase 0 Decitabine + Tetrahydrouridine p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies Completed USA 0
NCT02875548 Phase II Tazemetostat Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study Enrolling by invitation USA | POL | GBR | FRA | BEL | AUS 1
NCT02909777 Phase I CUDC-907 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma Active, not recruiting USA 0
NCT02911142 Phase Ib/II Cyclophosphamide + Doxorubicin + Etoposide + Lenalidomide + Prednisone + Rituximab + Vincristine Sulfate Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma Active, not recruiting USA 0
NCT02922764 Phase I RGX-104 Ipilimumab + RGX-104 Nivolumab + RGX-104 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RGX-104 A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma Active, not recruiting USA 0
NCT02932280 Phase Ib/II Neratinib Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment Active, not recruiting USA | CAN 0
NCT02935907 Phase I Alrizomadlin APG-115 in Patients With Advanced Solid Tumors or Lymphomas Completed USA 0
NCT02992483 Phase I MIK665 Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma Completed USA | ITA | FRA | ESP | DEU | AUS 1
NCT03005782 Phase I Cemiplimab + Fianlimab Fianlimab Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers Completed USA | IRL | GBR | AUS 1
NCT03010176 Phase I Pembrolizumab + Ulevostinag Ulevostinag Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001) Completed USA | ISR | GBR | FRA 1
NCT03013218 Phase I Evorpacept Atezolizumab + Evorpacept Evorpacept + Trastuzumab A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma Active, not recruiting USA 1
NCT03013491 Phase II CX-072 + Ipilimumab CX-072 + Vemurafenib CX-072 A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas Completed USA | POL | NLD | GBR | ESP 1
NCT03017820 Phase I VSV-hIFNbeta-NIS VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma Recruiting USA 0
NCT03030417 Phase I LMP744 Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas Completed USA 0
NCT03061188 Phase I Nivolumab + Veliparib Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes Completed USA 0
NCT03155620 Phase II Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting USA | CAN | AUS 1
NCT03162536 Phase I ARQ 531 Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies Active, not recruiting USA 0
NCT03172936 Phase I MIW815 + Spartalizumab Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas Terminated USA | NLD | ESP | DEU | CHE | CAN | AUS 1
NCT03192202 Phase Ib/II AFM13 AFM13 in Relapsed/Refractory Cutaneous Lymphomas Completed USA 0
NCT03194893 Phase III Crizotinib Alectinib A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer Recruiting USA | TUR | POL | ITA | FRA | ESP 4
NCT03199586 Phase I NP-G2-044 Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) Completed USA 0
NCT03205176 Phase I AZD5153 Phase I Study of AZD5153 in Patients With Relapsed or Refractory Solid Tumors and Lymphomas Completed USA | CAN 0
NCT03229200 FDA approved Ibrutinib Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. Enrolling by invitation USA | TUR | SWE | POL | NZL | ITA | HUN | GBR | FRA | ESP | CZE | CAN | AUS 4
NCT03229278 Phase I Nivolumab + Pembrolizumab + Trigriluzole Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma Completed USA 0
NCT03241940 Phase I Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies Recruiting USA 0
NCT03249792 Phase I MK-2118 + Pembrolizumab MK-2118 Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) in the Treatment of Adults With Advance/Metastatic Solid Tumors or Lymphomas (MK-2118-001) Terminated USA | ISR 0
NCT03259503 Phase Ib/II Busulfan Olaparib Vorinostat Palifermin Gemcitabine Melphalan Dexamethasone Pyridoxine Rituximab Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas Active, not recruiting USA 0
NCT03291938 Phase I IACS-010759 Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Solid Tumors and Lymphoma Completed USA 0
NCT03309878 Phase Ib/II Pembrolizumab Mogamulizumab + Pembrolizumab Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Lymphomas Completed USA 0
NCT03311412 Phase I Sym021 Sym021 (Anti-PD-1) in Patients With Advanced Solid Tumor Malignancies or Lymphomas Completed USA | CAN 0
NCT03316573 Phase II Pembrolizumab A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas Suspended USA 0
NCT03322384 Phase Ib/II Epacadostat + SD-101 Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma Completed USA 0
NCT03323034 Phase I Irinotecan + MLN4924 + Temozolomide Pevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma Completed USA 0
NCT03323398 Phase I mRNA-2416 Dose Escalation Study of mRNA 2416 for Intratumoral Injection to Patients With Advanced Malignancies Terminated USA 0
NCT03332355 Phase I PAC-1 + Temozolomide Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2 Terminated USA 0
NCT03359733 Phase I Mivavotinib A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor Withdrawn USA 0
NCT03365791 Phase II Ieramilimab Spartalizumab PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Completed USA 0
NCT03418038 Phase II Dexamethasone Carboplatin + Etoposide + Ifosfamide Carboplatin + Etoposide + Ifosfamide + Rituximab Cisplatin + Cytarabine + Dexamethasone Cisplatin + Dexamethasone + Gemcitabine Rituximab Cytarabine + Dexamethasone + Oxaliplatin Gemcitabine + Oxaliplatin Cisplatin + Cytarabine + Dexamethasone + Rituximab Ascorbic Acid and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma Recruiting USA 0
NCT03435250 Phase I AG-270 + Docetaxel AG-270 + Gemcitabine + Nab-paclitaxel AG-270 Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss Terminated USA | FRA | ESP 0
NCT03445858 Phase I Decitabine + Pembrolizumab Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults Completed USA 0
NCT03448393 Phase I Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies Recruiting USA 0
NCT03451825 Phase Ib/II Avelumab Phase I/II Study of Avelumab in Pediatric Cancer Subjects Terminated USA | DNK | CAN | BEL 1
NCT03458728 Phase Ib/II Copanlisib Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients Terminated USA 0
NCT03478462 Phase I CLR 131 Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma Active, not recruiting USA | CAN | AUS 0
NCT03489343 Phase I Sym023 Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas Completed USA | CAN 0
NCT03489369 Phase I Sym022 Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas Completed USA | CAN 0
NCT03502733 Phase I Copanlisib + Nivolumab Copanlisib and Nivolumab in Treating Patients With Metastatic Solid Tumors or Lymphoma Active, not recruiting USA 0
NCT03505554 Phase II Lorlatinib A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma (CRU3) Recruiting ITA 0
NCT03530683 Phase I TTI-622 A Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma Terminated USA 0
NCT03556228 Phase I VMD-928 Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Recruiting USA 1
NCT03648372 Phase I Subasumstat A Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Metastatic Solid Tumors or Lymphomas Terminated USA 0
NCT03654716 Phase I ALRN-6924 + Cytarabine ALRN-6924 Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer Completed USA 0
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Active, not recruiting USA | AUS 4
NCT03739931 Phase I mRNA-2752 mRNA-2752 + Tremelimumab Durvalumab + mRNA-2752 Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Patients With Advanced Malignancies Active, not recruiting USA | ISR | AUS 0
NCT03763149 Phase I IBI188 A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas Completed USA 0
NCT03770000 Phase Ib/II Romidepsin + Tenalisib Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma Completed USA 0
NCT03775525 Phase I Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma (GEN602) Active, not recruiting USA 0
NCT03779113 Phase Ib/II HMPL-523 An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma Active, not recruiting USA | POL | ITA | FRA | FIN | ESP | DNK 0
NCT03815682 Phase I Pembrolizumab + RPTR-147 RPTR-147 RPTR-147 in Patients With Selected Solid Tumors and Lymphomas Terminated USA 0
NCT03841110 Phase I FT500 + Pembrolizumab Atezolizumab + FT500 FT500 + Nivolumab FT500 FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors Completed USA 0
NCT03856216 Phase II Methotrexate Filgrastim + Methotrexate + Rituximab Rituximab Bendamustine + Fludarabine + Inotuzumab ozogamicin + Tacrolimus Filgrastim + Methotrexate Inotuzumab ozogamicin Fludarabine + Inotuzumab ozogamicin + Melphalan + Tacrolimus anti-thymocyte globulin Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation Recruiting USA 0
NCT03871348 Phase I SAR441000 Cemiplimab + SAR441000 A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors Terminated USA | NLD | FRA | ESP | DEU | BEL 0
NCT03884556 Phase I Gemcitabine + Nab-paclitaxel + TTX-030 Docetaxel + TTX-030 Pembrolizumab + TTX-030 TTX-030 TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers Completed USA 0
NCT03934372 Phase Ib/II Ponatinib Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors Recruiting SWE | NLD | ITA | GBR | FRA | ESP | DNK | DEU | BEL 0
NCT03934814 Phase I Lemzoparlimab Lemzoparlimab + Pembrolizumab Lemzoparlimab + Rituximab Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma Completed USA 1
NCT03936465 Phase I BMS986158 CC-90010 Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Completed USA | CAN 0
NCT04053673 Phase I RBN-2397 RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors , FIH, MAD Study Unknown status USA | ESP 0
NCT04111107 Phase II Precision Medicine for Patients With Identified Actionable Mutations Terminated USA 0
NCT04130516 Phase Ib/II LNS8801 LNS8801 + Pembrolizumab Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab Recruiting USA 0
NCT04137900 Phase I Icatolimab Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies Recruiting USA 0
NCT04138875 Phase II Bendamustine + Brentuximab vedotin + Rituximab Brentuximab vedotin + Rituximab A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB) Withdrawn USA 0
NCT04144140 Phase I E7766 Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101 Terminated USA | GBR | FRA | ESP 1
NCT04167137 Phase I SYNB1891 Atezolizumab + SYNB1891 Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Subjects Terminated USA 0
NCT04186637 Phase I ALPN-202 An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1) Terminated USA | AUS 0
NCT04189445 Phase II Futibatinib Futibatinib in Patients With Specific FGFR Aberrations Active, not recruiting USA | TUR | SWE | NLD | ITA | GBR | FRA | ESP | DEU | BEL 5
NCT04189952 Phase II Acalabrutinib + Carboplatin + Etoposide + Ifosfamide + Rituximab Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma Terminated USA 0
NCT04195555 Phase II Ivosidenib Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA | AUS 1
NCT04214093 Phase I AZD0466 A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors Terminated USA 0
NCT04243499 Phase I ICT01 First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) Recruiting USA | GBR | FRA | ESP | DEU | BEL 0
NCT04254107 Phase I SGN-TGT Pembrolizumab + SGN-TGT A Safety Study of SGN-TGT in Patients With Advanced Cancer Terminated USA | ITA | GBR | FRA | ESP | CAN 0
NCT04257617 Phase I ZL1201 A Trial of ZL-1201 in Subjects With Advanced Cancer Completed USA 1
NCT04261439 Phase I NIZ985 NIZ985 + Spartalizumab A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab Terminated USA | ITA | ESP | DEU | BEL 2
NCT04283097 Phase I KPG-818 Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects Recruiting USA 0
NCT04284774 Phase II Tipifarnib Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Active, not recruiting USA 1
NCT04285268 Phase II Bortezomib + Rituximab + Venetoclax Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Withdrawn USA 0
NCT04306224 Phase I IMC-002 A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas Completed USA 1
NCT04464798 Phase I Iberdomide Iberdomide + Obinutuzumab Iberdomide + Rituximab A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas Active, not recruiting USA | ITA | FRA | DEU 2
NCT04500548 Phase I Nivolumab Ipilimumab + Nivolumab Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study Withdrawn USA | CAN 0
NCT04571138 Phase Ib/II SCRI-CAR22v2 A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma Recruiting USA 0
NCT04588922 Phase I GFH009 A Study of GFH009 in Patients With Hematologic Malignancies Recruiting USA 1
NCT04609579 Phase I SNX281 Pembrolizumab + SNX281 Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma Terminated USA 0
NCT04639843 Phase I Azacitidine + Doxorubicin + Duvelisib + Romidepsin Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma Withdrawn USA 0
NCT04870944 Phase Ib/II CBL0137 CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma Recruiting USA | AUS 0
NCT04925544 Phase II VK-2019 Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV) Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV) Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies Recruiting USA 0
NCT04970992 Phase I DZ-002 A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma Recruiting USA 0
NCT05011058 Phase II CHR-3996 CHR-3996 + Valganciclovir An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1) Recruiting USA | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | AUS 5
NCT05020678 Phase I Cyclophosphamide + Fludarabine NKX019 NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers Recruiting USA | AUS 0
NCT05053971 Phase Ib/II Entinostat + ZEN-3694 Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas Recruiting USA 0
NCT05065866 Phase I Azacitidine + Duvelisib Duvelisib in Combination With CC-486 in Lymphoid Malignancy Active, not recruiting USA 0
NCT05071209 Phase Ib/II Elimusertib Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors Active, not recruiting USA | CAN 0
NCT05093322 Phase Ib/II Gemcitabine + Surufatinib A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors Completed USA 0
NCT05115292 Phase I BJ-005 A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma Active, not recruiting USA 0
NCT05225584 Phase I KT-333 Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors Active, not recruiting USA 0
NCT05290597 Phase I IBI363 A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas Unknown status AUS 0
NCT05337735 Phase II XmAb20717 A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers Suspended USA 0
NCT05463263 Phase Ib/II STP938 A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas Recruiting USA | GBR | FRA 0
NCT05544968 Phase Ib/II CD30biAb-AATC CD30biAb-AATC for CD30+ Malignancies Not yet recruiting USA 0
NCT05627245 Phase I Belinostat + Tazemetostat Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment Recruiting USA 0
NCT05698888 Phase I VP301 Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors Terminated USA 0
NCT05705570 Phase I Cyclophosphamide + Fludarabine MB-CART19.1 A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies (CARTHIAE-1) Not yet recruiting BRA 0
NCT05751798 Phase Ib/II OSE-279 Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas Recruiting FRA | BEL 0
NCT05775406 Phase I KT-253 Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors Active, not recruiting USA 0
NCT05807035 Phase I Radvax Autologous Tumour Vaccine Trial Recruiting AUS 0
NCT05878691 Phase I GRC 54276 + Pembrolizumab Atezolizumab + GRC 54276 GRC 54276 A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas. Active, not recruiting USA 1
NCT06022029 Phase I ONM-501 Cemiplimab + ONM-501 A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. (ON-5001) Recruiting USA | AUS 0
NCT06092580 Phase I AWT020 Phase 1 Study of AWT020 in Advanced Cancer Recruiting AUS 0
NCT06208657 Phase Ib/II GDC-0084 + Irinotecan + Temozolomide Pimasertib Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer Recruiting CAN | AUS 0
NCT06223542 Phase I TAK-243 Studying TAK-243 in Patients With Advanced Cancer Recruiting USA 0
NCT06326463 Phase I CD70-CAR-T cells Cyclophosphamide + Fludarabine Mesna CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies Recruiting USA 0
NCT06345027 Phase I CD70-CAR-T cells CHIMERIC ANTIGEN RECEPTOR TREATMENT TARGETING CD70 (SEVENTY) (CASEY) Not yet recruiting USA 0